|
Match
|
Document |
Document Title |
|
|
7641901 |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
|
|
|
7488808 |
Janus family kinases and identification of immune modulators
An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains,...
|
|
|
7446177 |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of...
|
|
|
7410767 |
HLA-E binding
The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells...
|
|
|
7390490 |
Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there...
|
|
|
7288254 |
Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and...
|
|
|
7211257 |
Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by...
|
|
|
7119065 |
Metal complex-protein composite and oxidation catalyst
We claim a metal complex-protein composite comprising a salen metal complex and an apoprotein having a cavity, wherein the salen metal complex has a structure given by the following formula:
R 1...
|
|
|
7074403 |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
|
|
|
7070777 |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
This invention provides for methods of inhibiting inflammation with antibodies that bind the 5c8 protein.
|
|
|
7067109 |
Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor...
|
|
|
7060803 |
Metal complex-protein composite and hydrogenation catalyst
A metal complex-protein composite comprising apohemoglobin, apoheme oxygenase, apocatalase or apoferrin having cavity and a metal complex has a specific structure that the metal complex is received...
|
|
|
7053190 |
Secreted protein HRGDF73
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
|
|
|
7052694 |
Dendritic cell potentiation
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are...
|
|
|
7045128 |
Antibodies against flt3-ligand
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is...
|
|
|
7041801 |
Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
The present invention relates to a member of a novel gene family referred to as developmentally-regulated endothelial cell locus-1 (del-1). In particularly, the invention related to del-1...
|
|
|
7030228 |
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods...
|
|
|
7005271 |
Method for the determination of the prethrombotic state
The present invention relates to determining the prethrombotic state, in particular determining an amount or presence of circulating microparticles and/or stimulated procoagulant cells.
|
|
|
6767996 |
Altered antibodies and their preparation
An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable...
|
|
|
6759519 |
Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor)
Antibodies against human G-protein chemokine receptor polypeptides, the polypeptides themselves, DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant...
|
|
|
6709833 |
Monoclonal antibody recognizing phosphatidylinositol-3,4-diphosphate
A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4-biphosphate (PI-3,4-P2) but does not cross-react with structurally similar phospholipid antigens is advantageous...
|
|
|
6692743 |
Apoptosis of naive human NK cells by crosslinking of their Fc&ggr RIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody
Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK...
|
|
|
6689359 |
Ligands, including antibodies, showing reactivity against endocrine cells
The invention provides monoclonal and polyclonal antibodies recognising molecules on secretory cells of various tissue targets of autoimmune disease allowing a unifying method of preventing and...
|
|
|
6677123 |
Process for detecting increased risk of fetal chromosomal abnormality
An increased risk of a fetal chromosomal abnormality, for example, fetal Down syndrome can be detected by separating or discriminating α-fetoproteins present in the body fluid of a pregnant woman,...
|
|
|
6667036 |
Methods of treatment using antibodies to P-selectin glycoprotein ligand
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3...
|
|
|
6613327 |
Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated...
|
|
|
6610834 |
Human IgM antibodies to chemokine receptors
Human sera from normal (i.e., non-HIV infected) individuals contain certain IgM autoantibodies reactive to chemokine and other lymphocyte-surface receptors. A subset of these IgM autoantibodies...
|
|
|
6576236 |
Methods for stimulating T cell responses by manipulating a common cytokine receptor &ggr chain
When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy....
|
|
|
6566082 |
T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy....
|
|
|
6551593 |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
The invention relates to the treatment of individuals suffering from a disease associated with leukocyte recruitment to the gastrointestinal tract or other tissues as a result of binding of...
|
|
|
6528625 |
Anti-CCR5 antibodies and kits comprising same
The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The...
|
|
|
6525180 |
Antibodies to mammalian T cell surface antigen
Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided....
|
|
|
6506382 |
Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3...
|
|
|
6503509 |
Method for receptor desensitization
Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell...
|
|
|
6489293 |
Recombinant human erythropoietin with altered biological activity
DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant...
|
|
|
6485928 |
Use of granulysin as an antimicrobial agent
The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population....
|
|
|
6479247 |
Dendritic cell-specific antibodies
Isolated antibody or preparation of antibodies comprising an antigen-binding domain wherein the antigen is present on activated dendritic cells and wherein the antibody does not interact with...
|
|
|
6464978 |
Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The...
|
|
|
6344545 |
Method for preventing HIV-1 infection of CD4&plus cells
This invention provides methods for inhibiting fusion of HIV-1 to CD4 + cells which comprise contacting CD 4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an...
|
|
|
6309639 |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3 ...
|
|
|
6277962 |
Receptor on the surface of activated t-cells: act-4
The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and...
|
|
|
6228600 |
Immunoassays for the alpha platelet-derived growth factor receptor
Recombinant DNA technology was used to clone encoding nucleic acids for the human alpha platelet-derived growth factor receptor (PDGF-R type alpha). Peptides corresponding to the predicted sequence...
|
|
|
6214974 |
Avidin-biotin immunoconjugates
The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing...
|
|
|
6197596 |
Monitoring and/or prognostic of antibody-mediated autoimmune diseases
The present invention relates to a method to determine antibody-mediated autoimmune diseases in a patient, which comprises the steps of: a) determining the amount of clusterin present in a serum,...
|
|
|
6197298 |
Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells. The substances...
|
|
|
6177547 |
Antibodies to P-selectin glycoprotein ligand
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3 ...
|
|
|
6165799 |
Detection of anti-Fc.sub.ε R autoantibodies in asthmatics
The present invention includes a method to detect chronic pulmonary diseases of the airways associated with anti-Fc ε R IgG autoantibodies. Preferred diseases to detect include atopic asthma and...
|
|
|
6159470 |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The...
|
|
|
6143873 |
Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof
This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the...
|
|
|
6143273 |
Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein
Soluble polypeptide fraction consisting of all or part of one at least one of the four immunoglobulin-type extracellular LAG-3 protein domains (amino acids 1-159, 160-230, 240-330 and 331-412 of...
|